Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects.

Medical hypotheses - 1 Dec 1996

Vandel P, Bonin B, Vandel S, Sechter D, Bizouard P

Abstract excerpt

Extrapyramidal symptoms occur as side-effects of neuroleptics. For many years, case reports of such side-effects, linked to antidepressant treatments, have been published, but this phenomenon is not well known. Tricyclic and serotonergic antidepressants are both involved. The authors present an hypothesis which provides one possible neurobiochemical explanation for the aetiology of these side-effects. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Enzyme Inhibitors
Share to Models, Biological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Source

Identifiers

PMID: 8961239
DOI: 10.1016/s0306-9877(96)90154-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects.PMID 8961239Read ↗

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.Semantic proximity Read ↗

[Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].Semantic proximity Read ↗

Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.Semantic proximity Read ↗

Pharmacogenetics and drug metabolism of newer antidepressant agents.Semantic proximity Read ↗

Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.Semantic proximity Read ↗

The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.Semantic proximity Read ↗

CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.Semantic proximity Read ↗

Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.Semantic proximity Read ↗

Exploring the role of drug-metabolising enzymes in antidepressant side effects.Semantic proximity Read ↗

Acute pharmacogenetic dystonic reactions in a family with the CYP2D6 *41 allele: a case report.Semantic proximity Read ↗

Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.Semantic proximity Read ↗

Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.